The Trump Administration has prioritized the elimination of overreaching regulations: In FY 2017, the Trump Administration reduced lifetime net regulatory costs across all agencies by $8.1 billion ($570 million per year)....more
12/12/2018
/ Accounting ,
Administrative Procedure Act ,
Department of Health and Human Services (HHS) ,
Disclosure Requirements ,
Electronic Medical Records ,
Health Care Providers ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare Reform ,
HITECH Act ,
Regulatory Agenda ,
Trump Administration
...Alexander: Senate Sends Opioids Legislation Called “Landmark” by Leader McConnell to President – On Wednesday, the U.S. Senate passed by a vote of 98-1, the SUPPORT for Patients and Communities Act, sponsored by Senator...more
10/11/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Electronic Medical Records ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Trump Administration
Here are some key health care policy headlines from the past week that you may have missed.
Congress -
Legislation and Committee Activity -
Bloomberg: Opioids Compromise Already in the Works in Congress – Congress is...more
9/27/2018
/ Acts of Congress ,
Centers for Medicare & Medicaid Services (CMS) ,
Continuing Resolution ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Gag Clauses ,
HELP ,
OMB ,
Opioid ,
Prescription Drugs ,
Proposed Rules ,
Regulatory Agenda ,
Telemedicine ,
Trump Administration
Congress is back in session after the August recess and, as expected, a flurry of activity took place. Here are some key health care policy headlines from the past week that you may have missed....more
9/13/2018
/ Acts of Congress ,
Affordable Care Act ,
Drug Pricing ,
HELP ,
HRSA ,
Opioid ,
Pharmacy Benefit Manager (PBM) ,
Primary Elections ,
Regulatory Agenda ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/24/2018
/ Appropriations Bill ,
Biosimilars ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Budget ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Legislative Committees ,
Medicaid ,
Medicare ,
Medicare Access and CHIP Reauthorization (MACRA) ,
Opioid ,
Secretary of HHS ,
Stark Law ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
7/2/2018
/ Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Fraud ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
New Legislation ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Section 340B ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration ,
Veterans Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/26/2018
/ Affordable Care Act ,
Agency Consolidation ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
SAMHSA ,
Stark Law ,
State and Local Government ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. *Please note that we publish this newsletter only...more
6/12/2018
/ Affordable Care Act ,
Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Cybersecurity ,
Department of Health and Human Services (HHS) ,
Federal Budget ,
Food and Drug Administration (FDA) ,
GAO ,
HELP ,
Legislative Agendas ,
Legislative Committees ,
Medicare ,
Medicare Part D ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Preventive Health Care ,
Substance Abuse ,
Trump Administration ,
Ways and Means Committee
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation....more
5/29/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Drug & Alcohol Abuse ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Health Care Providers ,
Infectious Diseases ,
Legislative Agendas ,
Medicare Part D ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Telemedicine ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more
5/21/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our second “Public Policy Weekly* Health Care Newsletter” in which we compile the latest health care policy news and legislation.
Please...more
5/14/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
DEA ,
Department of Health and Human Services (HHS) ,
Department of Veterans Affairs ,
Drug Pricing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Health Insurance ,
Health Insurance Portability and Accountability Act (HIPAA) ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicaid ,
Medicare Part C ,
Mental Health ,
National Institute of Health (NIH) ,
Pharmaceutical Industry ,
Prescription Drugs ,
Regulatory Agenda ,
Section 340B ,
Social Security Act ,
Trade Policy ,
Trump Administration